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ABSTRACT
Background: Although the efﬁcacy of platelet glycoprotein
IIb/IIIa inhibitors (GPIIb/IIIa) in reducing complication rates
during percutaneous coronary intervention (PCI) is well
established, comparative studies assessing currently approved
agents as administered in current practice are limited. We
studied the clinical and length of stay (LOS) outcomes of
patients undergoing PCI who received either abciximab or
eptiﬁbatide.
Methods: All patients undergoing elective, urgent, or emer-
gency PCI at Mayo Clinic Rochester between November 17,
2000 and August 31, 2004 who received either abciximab
or eptiﬁbatide were included. Clinical, angiographic, and
follow-up data were prospectively recorded in the Mayo
Clinic PCI Registry; administrative data recorded LOS. We
used logistic and Cox proportional hazard models to estimate
the risk of adverse events and generalized linear modeling to
predict LOS. Propensity score and standard risk adjustments
were used to account for baseline differences.
Results: A total of 2123 PCI patients received eptiﬁbatide
and 951 received abciximab. The adjusted odds ratio for
in-hospital death and myocardial infarction (MI) with epti-
ﬁbatide was 0.80 (95% CI 0.56–1.14, P = 0.21) versus
abciximab. Adjusted hazard ratios for death and MI and
for death, MI, or target vessel revascularization during a
median follow-up of 24.6 months were 0.84 (95% CI 0.68–
1.02, P = 0.08) and 0.95 (95% CI 0.81–1.11, P = 0.53),
respectively. Adjusted postprocedural LOS was similar at
3.4 days.
Conclusion: This large observational study found no evi-
dence of a clinical or LOS advantage to physician choice of
either abciximab or eptiﬁbatide during PCI in contemporary
practice.
Keywords: angioplasty, length of stay, platelet glycoprotein
IIb/ IIIa inhibitor.
Introduction
Platelet glycoprotein (GP) IIb/IIIa inhibitors have been
consistently shown to improve clinical outcomes
among a broad spectrum of patients treated with per-
cutaneous coronary interventions (PCI) [1–9]. This
class of drugs acts by binding the platelet GP IIb/IIIa
receptor, thereby inhibiting platelet aggregation,
thrombus formation, and ischemic complications.
Two platelet GP IIb/IIIa inhibitors have been
approved by the U.S. Food and Drug Administration
for use as adjunctive therapy in patients undergoing
PCI: abciximab (ReoPro®, Eli Lilly & Co., Indianapo-
lis, IN, USA) and eptiﬁbatide (Integrilin®, Millennium
Pharmaceuticals, Inc., Cambridge, MA, USA). Trials to
date indicate that the use of abciximab administered
during PCI reduces the frequency of ischemic compli-
cations compared with placebo in both elective and
acute myocardial infarction (MI) cases [1–4]. Similarly,
the Enhanced Suppression of the Platelet IIb/IIIa
Receptor with Integrilin Therapy (ESPRIT) trial dem-
onstrated that treatment with eptiﬁbatide reduced the
frequency of ischemic complications (compared with
placebo) among patients undergoing elective or urgent
PCI [5–9]. Meta-analyses suggest a survival beneﬁt at
30 days with the use of GP IIb/IIIa inhibitors during
PCI and a potential for sustained survival advantage
during longer follow-up [10–12]. Subsequent cost-
effectiveness estimates suggest that these agents
provide good value when utilized as adjunctive therapy
during PCI [13–16].
The American College of Cardiology/American
Heart Association guidelines for PCI recommend the
use of GP IIb/IIIa inhibitors, particularly in patients
with acute coronary syndromes or other high-risk
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angiographic characteristics [17]. It remains unclear
whether structural and pharmacodynamic differences
between these agents result in varying clinical or eco-
nomic outcomes [18–25]. Abciximab and eptiﬁbatide
have widely disparate acquisition costs [15]. To our
knowledge, no large-scale comparative study has
assessed patient outcomes associated with these agents
as currently administered adjunctive to PCI. The
primary objective of this study, therefore, was to esti-
mate the effect of abciximab and eptiﬁbatide use
during PCI on clinical outcomes and length of stay
(LOS) with dosing regimens used in contemporary
practice.
Methods
Study Population
All patients undergoing elective, urgent, or emergency
PCI at Mayo Clinic Rochester, Minnesota between
November 17, 2000 and August 31, 2004 who
received either abciximab or eptiﬁbatide adjunctive to
PCI were included in the analysis. The start date was
chosen to reﬂect implementation of the accelerated,
double-bolus eptiﬁbatide dosing regimen (as studied in
the ESPRIT trial) as standard practice at our institu-
tion. In the case of multiple qualifying procedures
for a single patient, only the earliest PCI within the
study period was considered in the analysis (“index”
hospitalization). Elective, staged procedures during the
index hospitalization were excluded as atypical events.
We obtained Institutional Review Board approval for
this study. All patients who did not grant authorization
to use their medical records in research were excluded
prior to data collection.
Medications
Glycoprotein IIb/IIIa inhibitor therapy was initiated in
the catheterization laboratory and continued after the
procedure. Eptiﬁbatide was administered in two bolus
infusions 10 minutes apart at 180 mg/kg followed by
an infusion at 2 mg/kg/min for 18 hours. Eptiﬁbatide
dosing was adjusted as needed for renal function.
Abciximab was administered as an intravenous bolus
of 0.25 mg/kg body weight and followed by an infu-
sion at 0.125 mg/kg/min for 12 hours. All patients
received 325 mg oral aspirin at the time of the pro-
cedure. For patients undergoing stent implantation,
clopidogrel was given as a 300 mg loading dose and
75 mg daily for 1 month (bare metal stents) to
6 months (drug-eluting stents). Bolus, weight-adjusted
heparin was administered to maintain an activated
clotting time of 200 to 250 seconds.
Data Sources and Outcome Measures
All patients undergoing PCI at Mayo Clinic have been
followed prospectively since 1979 according to a well-
established protocol, the Mayo Clinic PCI Registry
[26]. This database contains baseline demographic,
clinical, and angiographic data as well as information
on patient outcomes during follow-up. All patients are
interviewed in person or by telephone at 6 months and
12 months after PCI and yearly thereafter to assess
major adverse cardiovascular events.
Angiographic characteristics and procedural suc-
cess are determined and documented by the PCI
operator. A blinded team of registered nurses and
data coordinators collect and enter all pre- and post-
procedural data, including the occurrence of adverse
clinical events. Blinded data adjudication is con-
ducted as needed by an interventional cardiologist
not the operator for the case in question. Ten percent
of records are audited for quality assurance by the
supervisor of the data coordinators. Medical records
for care received for these events at Mayo Clinic and
other institutions are obtained for review with the
patient’s written informed authorization to release
such information.
We used this registry to identify our study popula-
tion, assess patient and procedural characteristics, and
track patient outcomes. Clinical outcomes of interest
included: procedural success (deﬁned as less than 50%
residual stenosis and without in-hospital death, MI,
or target vessel revascularization [TVR]); in-hospital
bleeding complications; in-hospital death or MI; and
death or MI during follow-up. A secondary composite
end point was death, MI, or TVR. Myocardial in-
farction was deﬁned as any two of the following
criteria: an episode of prolonged angina lasting 20 or
more minutes; a rise in the serum creatine kinase
(CK)-MB isoenzyme greater than twofold normal; or
ST-segment/T-wave changes or new Q-waves on serial
electrocardiograms indicative of myocardial damage.
Routine measurement of cardiac biomarkers was stan-
dard practice during the study duration. CK-MB isoen-
zymes were drawn at the time of the procedure and at
8, 16, and 24 hours as well as in the event of an
ischemic complication. The economic outcome of
interest was LOS (tracked in days and hours) associ-
ated with the patient’s PCI procedure. Administrative
data sources were used to assess this hospital LOS
(deﬁned as the number of days/hours from the date of
procedure to hospital discharge date).
Statistical Analysis
Continuous variables are reported as means 
standard deviation, and categorical variables are
reported as frequencies and percentages. Patient char-
acteristics and in-hospital outcomes between treatment
groups were compared using t-tests and chi-square
tests, as appropriate. Ordered categorical variables
(e.g., percent elective vs. percent urgent vs. percent
emergency PCI) were compared using the Wilcoxon
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rank-sum test. We used the log-rank test to compare
Kaplan–Meier estimated event rates during follow-up
between groups.
We used propensity score methods to account for
observed potential confounding factors and treatment
selection bias [27,28]. Propensity score methods are
applied in nonrandomized clinical and health services
research studies to identify patient groups who are
similar in pretreatment characteristics but who differ
in treatment assignment [29–31].
We used multivariate logistic regression to assess
the likelihood (propensity score) patients received epti-
ﬁbatide rather than abciximab adjunctive to PCI based
on demographic, clinical, and angiographic character-
istics. Speciﬁc covariates considered in the ﬁnal logistic
model included age, date of procedure, urgency of
PCI (elective or emergency), preprocedural shock, MI
within 24 hours of PCI, Canadian Cardiovascular
Society Class 3 or higher angina, diabetes, body mass
index, smoking status, history of prior MI, history of
prior PCI, renal insufﬁciency, left main stenosis more
than 70%, type B2 or C lesion, moderate or severe
bend in lesion, presence of a thrombus-containing
lesion, maximum stent size placed, and the Mayo
Clinic Risk Score [32,33]. Covariates were selected
based on clinical relevance, signiﬁcance on univariate
comparison by treatment group, and signiﬁcance in
preliminary logistic models. Linear models and
Cochran–Mantel–Haenszel statistics were used to
assess covariate balance after accounting for propen-
sity score quintiles.
Patients were stratiﬁed into ﬁve equal-sized groups
based on their estimated propensity score (deﬁned as
the log-odds of receiving eptiﬁbatide vs. abciximab).
Patients with extreme (high and low) estimated pro-
pensity scores were excluded in adjusted analyses. We
used logistic regression to estimate adjusted odds
ratios for in-hospital events within each stratum. Cox
proportional hazard models were used to estimate
hazard ratios for the rate of adverse events after PCI
also within stratum. The start point in all survival
analyses was deﬁned as the time of procedure (i.e.,
in-hospital events were included). Within-group esti-
mates of treatment effects were combined by inverse-
variance means to create an overall estimated effect.
Generalized linear modeling was used to assess
LOS, assuming a negative binomial distribution func-
tion with log link. This model speciﬁcation has been
widely used for non-negative and skewed count data
and has been applied in previous analyses assessing the
effect of GP IIb/IIIa use on length of hospital stay
[25,34]. Final models included a treatment indicator
variable, propensity score, as well as additional demo-
graphic, clinical, angiographic, and procedural charac-
teristics thought to be theoretically predictive of LOS.
Prediction models of LOS also included baseline
summary severity measures (clinical and economic)
based on the listed International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation diagnosis
codes for pre-existing conditions, along with Disease
Staging software [35]. All statistical tests were two-
sided, and P-values less than 0.05 were considered
signiﬁcant. SAS version 8.2 (SAS Institute Inc., Cary,
NC, USA) was used for all analysis.
Results
A total of 5584 patients underwent PCI during the
study duration, 3213 (57.5%) of whom received
abciximab or eptiﬁbatide as adjunctive phamaco-
therapy. Ninety-three patients denied research autho-
rization and were excluded. In addition, we excluded
320 PCI episodes from analysis because of multiple GP
IIb/IIIa inhibitor use or the existence of multiple quali-
fying PCIs per patient. The ﬁnal study cohort consisted
of 3074 patients of whom 951 (30.9%) received
abciximab and 2123 (69.1%) received eptiﬁbatide as
adjunctive therapy.
Table 1 shows the baseline and procedural charac-
teristics by GP IIb/IIIa inhibitor used. The two cohorts
were similar in terms of gender (approximately 70%
male), the rate of congestive heart failure on presenta-
tion, hypertension, and prior coronary artery bypass
graft surgery. The number of diseased vessels, the
number of vessels and segments treated, and the
number of stents placed (1.6 on average) were also
similar between treatment groups. The abciximab-
treated cohort, however, had a higher body mass
index, more recent MIs (within 24 hours or less of
PCI), more cases of emergency PCI, and more diabetic
patients (32% vs. 24%; P < 0.001). Patients receiving
abciximab were also more likely to smoke, have a
prior MI, a B2- or a C-type lesion, or a thrombus-
containing lesion, compared with patients who
received eptiﬁbatide.
Observed Outcomes
Observed in-hospital outcomes by the GP IIb/IIIa
inhibitor group are shown in Table 2. In-hospital rates
of death and all composite end points (death or any
MI, death or any Q-wave MI, and death, any MI, or
TVR) were similar between groups. Overall, proce-
dural success rates did not differ between groups (90%
vs. 92%; P = 0.07). Patients treated with abciximab
had signiﬁcantly more femoral bleeds and more blood
loss requiring transfusion (9% vs. 6%; P = 0.002).
Other bleeding complication rates (such as gastrointes-
tinal bleeds) were similar between cohorts. A hospital
LOS difference of 13.6 hours was observed in favor of
eptiﬁbatide treatment.
Figure 1 shows the Kaplan–Meier estimated prob-
ability of remaining free of death or MI during a
median follow-up of 24.6 months by GP IIb/IIIa
inhibitors. Eptiﬁbatide was associated with a signiﬁ-
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cantly lower risk of these combined events (estimated
death/MI rate at 2 years: 18.0% vs. 15.5%; P =
0.013). When TVR was added to the composite end
point, the difference also favored eptiﬁbatide treat-
ment, although this difference was of borderline statis-
tical signiﬁcance (estimated death/MI/TVR rate at
1 year: 22.5% vs. 20.3%; P = 0.08).
Propensity Score Analysis
According to the propensity score model, the estimated
probability of receiving eptiﬁbatide over abciximab
ranged from 13% to 98% in all eligible patients. The
goodness-of-ﬁt for the propensity score as assessed by
the c-statistic was 0.73, indicating good discrimination
between treatment groups. Fifty-eight patients were
excluded from further analyses because of extreme
(high or low) propensity scores. The remaining 3016
were divided into ﬁve groups of nearly equal size based
on propensity score quintiles. For each covariate, the
association between covariate and treatment assign-
ment adjusted for propensity score group was tested.
No adjusted associations were statistically signiﬁcant.
Baseline and procedural characteristics (such as body
mass index, urgency of PCI, prior or recent MI, lesion
type, multivessel disease, preprocedural shock, and
drug-eluting stent use (Fig. 2A–C) were well-balanced
within these propensity score subgroups. Within
individual quintiles, few characteristics had statisti-
cally signiﬁcant different distributions. Speciﬁcally,
eptiﬁbatide-treated patients in quintile 3 had more dia-
betics (31% vs. 22%; P = 0.04) as well as more current
smokers and patients with peripheral vascular disease
in quintile 2 (28% vs. 20%; P = 0.02 and 13% vs. 5%;
P = 0.003, respectively). Abciximab-treated patients
were more likely to have renal disease in quintile 4
(2% vs. 0%; P = 0.03), a thrombus in any lesion in
quintile 5 (33% vs. 18%; P = 0.01), and more multi-
vessel interventions in quintile 3 (73% vs. 81%;
P = 0.03).
Table 3 shows the estimated odds ratios for
in-hospital events and the estimated hazard ratios for
events during follow-up in the remaining sample
of 945 and 2071 abciximab- and eptiﬁbatide-treated
patients, respectively. We present results analyzed
separately within each propensity score quintile as well
as the combined estimated effect. The adjusted odds
ratio for in-hospital death and MI with eptiﬁbatide use
ranged from 0.44 to 1.30 with a combined estimate
of 0.80 (95% conﬁdence interval [CI] 0.56–1.14,
P = 0.21) compared with abciximab treatment. The
adjusted odds ratio for in-hospital death, MI, or TVR
with eptiﬁbatide use ranged from 0.53 to 1.13 with a
combined estimate of 0.84 (95% CI 0.61–1.15) com-
pared with abciximab treatment. Similarly, choice of
agent did not signiﬁcantly affect the estimated hazard
for death, MI, or TVR during follow-up (hazard ratio
estimate 0.95; 95% CI 0.81–1.11; P = 0.53).
LOS Analysis
Multivariate models assessing LOS were developed to
evaluate whether choice of GP IIb/IIIa inhibitor used
during PCI conferred an economic advantage. In these
adjusted analyses, agent used as adjunctive therapy
was not independently associated with LOS (whether
measured in hours or days) after controlling for pro-
pensity score and other clinical characteristics that dif-
fered at baseline between treatment groups. Models
predict LOS to be similar, estimated at 92.6 hours
and 92.9 hours, on average, for abciximab- and
eptiﬁbatide-treated patients, respectively (P = 0.98).
Table 1 Baseline characteristics*
Variable
Abciximab
(n = 951)
Eptiﬁbatide
(n = 2123) P-value
Age, years 65.0 12.4 66.2 12.1 0.02
Male gender (No./%) 680 (72) 1494 (70) 0.52
Body-mass index 30.4 6.0 29.9 5.7 0.02
Unstable angina 456 (48) 1159 (55) <0.001
MI 1–7 days before procedure 153 (16) 377 (18) 0.26
Preprocedural shock 54 (6) 72 (3) 0.003
MI day of procedure or 24 hours 303 (32) 474 (23) <0.001
Urgency of PCI <0.001
Elective 248 (26) 607 (29)
Urgent 405 (43) 1074 (51)
Emergency 298 (31) 441 (21)
CHF on presentation 121 (13) 243 (11) 0.31
Diabetes 299 (32) 515 (24) <0.001
Hypertension 634 (71) 1475 (73) 0.31
Peripheral vascular disease 79 (9) 198 (10) 0.39
Moderate/severe renal disease† 44 (5) 41 (2) <0.001
Current smoker 225 (24) 405 (19) 0.01
Prior MI 588 (63) 1166 (56) <0.001
Prior PCI 197 (21) 515 (24) 0.03
Prior CABG 154 (16) 373 (18) 0.34
EF 40 112 (12) 204 (10) 0.07
Number of diseased vessels
(70/50 deﬁnition)‡
0.65
0 15 (2) 41 (2)
1 254 (28) 562 (28)
2 348 (39) 768 (39)
3 285 (32) 613 (31)
B2- or C-type lesion 729 (86) 1577 (81) <0.001
Thrombus in lesion 386 (43) 652 (33) <0.001
Calciﬁed artery 289 (34) 740 (39) 0.01
Eccentric lesion 703 (91) 1492 (84) <0.001
Bifurcation lesion 152 (17) 261 (13) 0.01
Ulcerated lesion 143 (17) 232 (12) 0.001
Ostial lesion 150 (23) 314 (21) 0.32
Moderate or severe bend in lesion 183 (20) 482 (24) 0.02
Major side-branches in lesion 210 (24) 424 (21) 0.16
TIMI Flow = 0 preprocedure 172 (25) 283 (19) <0.001
Number of segments treated 1.6 0.8 1.6 0.8 0.56
Total number of vessels treated 0.48
1 771 (81) 1744 (82)
2 166 (17) 350 (16)
3 13 (1) 28 (1)
Total number of stents placed 1.6 1.0 1.5 1.1 0.90
*For variables with missing data, the percentages reﬂect the percent of those with
data available.
†Moderate/severe renal disease deﬁned as serum creatinine of >3 mg/dl.
‡Number of diseased vessels with at least one vessel having 70% stenosis and
subsequent vessels with at least 50% stenosis; the left main and left anterior
descending vessels were counted as one vessel.
CABG, coronary artery bypass graft; CHF, congestive heart failure; EF, ejection
fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI,
thrombolysis in myocardial infarction.
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Mean adjusted LOS, measured in days, was also
similar between groups predicted at 3.4 days.
Discussion
Our objective was to compare clinical and LOS out-
comes of patients undergoing PCI who received either
abciximab or eptiﬁbatide as adjunctive pharmaco-
therapy. To our knowledge, no randomized controlled
trial addressing the relative efﬁcacy or cost-
effectiveness of these medications is being planned.
Furthermore, it is unlikely that such a trial will ever be
conducted given the liberal use of eptiﬁbatide in
current practice and associated difﬁculties in securing
funding for such research. To date, however, this is the
largest reported direct comparison of these agents as
administered in contemporary PCI practice. The main
ﬁnding of our study is that eptiﬁbatide and abciximab
treatment groups had similar rates of adverse clinical
events (death, MI, and TVR) both in-hospital and
during a median follow-up of 2 years. Results of our
Table 2 Observed in-hospital outcomes
Variable
Abciximab
(n = 951) No./(%)
Eptiﬁbatide
(n = 2123) No./(%) P-value
Blood loss requiring transfusion 81 (9) 118 (6) 0.002
Femoral bleed 11 (1) 10 (0.5) 0.03
Hematoma >4 cm 35 (4) 62 (3) 0.26
Central nervous system bleed 0 (0) 0 (0)
Gastrointestinal bleed 18 (2) 27 (1) 0.18
Retroperitoneal bleed 6 (1) 5 (0.2) 0.09
Death 18 (2) 27 (1) 0.19
Death/any MI 70 (7) 118 (6) 0.06
Death/Q-wave MI 35 (4) 59 (3) 0.18
Death/any MI/TVR* 79 (8) 140 (7) 0.09
Procedural success† 860 (90) 1961 (92) 0.07
Length of stay (days)‡ 3.66 3.10 0.003
Length of stay (hours)‡ 88.9 75.3 0.002
*Target vessel revascularization (CABG or re-PCI).
†Procedural success deﬁned as <50% residual stenosis and without in-hospital death, MI, or target vessel revascularization.
‡Length of stay analyses exclude in-hospital deaths and patients with missing billing data; a resulting sample of 932 abciximab-treated and 2096 eptiﬁbatide-treated patients.
CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention;TVR, target vessel revascularization.
Figure 1 Kaplan–Meier survival curve relating choice of glycoprotein
IIb/IIIa inhibitor used to time to death or myocardial infarction.
(a)
(b)
(c)
Figure 2 (a) Proportion of patients presenting with emergency percuta-
neous coronary intervention (PCI). (b) Myocardial infarction within
24 hours of PCI. (c) B2- or C-type lesions (by treatment group and
propensity score quintile). Propensity score quintiles vary from 1 (least
likely to receive eptiﬁbatide) to 5 (most likely to receive eptiﬁbatide).
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economic analyses also found no LOS advantage
(analyzed in hours or days) associated with choice of
GP IIb/IIIa inhibitor.
Other studies have observationally or prospectively
compared clinical outcomes associated with these GP
IIb/IIIa inhibitors [20–23]. As in our study, they report
data suggesting that eptiﬁbatide- and abciximab-
treated patients experience similar short-term out-
comes. All of these studies, however, suffer from
limited statistical power to detect differences and only
analyzed patients treated with eptiﬁbatide when a
single-bolus dosing regimen, not reﬂective of current
practice, was used [5]. A recent contemporary analysis
by Deliargyris et al. [24] compared clinical outcomes
in 495 consecutive PCI patients treated by a single
operator. In contrast to our results, they observed
superior in-hospital and 30-day clinical outcomes
among abciximab-treated patients. Unlike our study,
however, they did not formally adjust for potential
confounding factors and treatment selection bias. A
limited sample size and single-operator outcomes limit
the generalizability of the ﬁndings.
Results of comparative economic analyses to date
have similar limitations and divergent conclusions
[20–22,25]. Investigators with the Prairie Reopro
versus Integrilin Cost Evaluation trial [20], for exam-
ple, found no difference in LOS among abciximab- and
eptiﬁbatide-treated elective PCI patients. Trial results,
however, suggested an average in-hospital cost differ-
ence of $723 and a 30-day difference of $749 signiﬁ-
cantly in favor of eptiﬁbatide use. Conversely, a large
observational analysis suggests a cost advantage for
abciximab with an estimated reduced total hospital
LOS of 0.83 days (P < 0.001) and postprocedural hos-
pital LOS of 0.48 days (P = 0.002) compared with
eptiﬁbatide [25]. Analyzing only hospital administra-
tive data, Lage et al. [25] had limited ability to control
for differences in clinical and angiographic character-
istics, which may, in part, have contributed to this
different economic conclusion. Moreover, GP IIb/IIIa
dosing regimens used as adjunctive therapy were also
not clear in the Lage study. Our large-scale contempo-
rary analysis assessed LOS while adjusting for baseline
differences in clinical and angiographic characteristics.
We did not ﬁnd evidence of reduced hospital stay asso-
ciated with choice of agent as adjunctive therapy.
Limitations
As a retrospective analysis of prospectively collected
data, our study has the methodological limitations of
such a design. Although comprehensive multivariate
adjustment was performed, our treatment groups may
have systematically differed in ways unaccounted for
by the multivariate analysis [36]. Nevertheless, we
included a large consecutive series of patients with a
wide spectrum of risk, unlike the relatively homog-
enous and low-risk patients generally enrolled in ran-
domized trials. We also had access to comprehensive
clinical data, with blinded data adjudication by
clinicians as needed, as well as administrative data
allowing adjustment for many observed factors likely
to inﬂuence physician choice of adjunctive therapy
and patient outcomes. The similarity of pretreatment
patient characteristics within propensity score sub-
groups suggests we were successful at reducing con-
founding by indication or choice of agent. Our study
reﬂects the experience of a single, high-volume referral
center. Patients and results may differ in other centers
and practice settings.
Conclusions
This is the largest direct comparison to date of eptiﬁ-
batide and abciximab, the two GP IIb/IIIa inhibitors
approved for adjunctive treatment during contempo-
rary PCI. In-hospital and 2-year clinical outcomes
are similar with use of eptiﬁbatide compared with
abciximab as adjunctive pharmacotherapy during PCI.
Table 3 Odds ratio and hazards ratio for adverse events with eptiﬁbatide compared with abciximab use
Propensity score group
In-hospital events* Follow-up events*
Death/MI Death/MI/TVR Death/MI Death/MI/TVR
Group 1—lowest PE 0.44 0.53 0.66 0.86
(0.22, 0.88) (0.28, 1.01) (0.46, 0.94) (0.65, 1.14)
Group 2 1.05 1.04 0.98 1.10
(0.51, 2.18) (0.54, 2.01) (0.67, 1.45) (0.80, 1.52)
Group 3 0.78 0.87 0.76 0.82
(0.40, 1.49) (0.46, 1.62) (0.51, 1.14) (0.59, 1.12)
Group 4 1.30
(0.53, 3.20)
1.13
(0.51, 2.50)
1.13
(0.65, 1.98)
1.08
(0.70, 1.68)
Group 5—highest PE 1.05
(0.31, 3.57)
0.86
(0.29, 2.54)
1.06
(0.46, 2.47)
1.29
(0.62, 2.65)
Combined estimate† 0.80
(0.56, 1.14)
0.84
(0.61, 1.15)
0.84
(0.68, 1.02)
0.95
(0.81, 1.11)
*Logistic regression was used to estimate odds ratios for in-hospital events and Cox proportional hazard models were used to estimate hazard ratios for the rate of adverse
events after PCI.Values shown in parentheses are 95% conﬁdence intervals.
†Within-group estimates were combined by inverse-variance weighted means to create an overall estimate.
PE, probability of receiving eptiﬁbatide; MI, myocardial infarction;TVR, target vessel revascularization (coronary artery bypass graft or re-percutaneous coronary intervention).
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Comparison of hospital LOS by treatment group sug-
gests no economic advantage to physician choice of GP
IIb/IIIa inhibitor. Additional comparative research is
warranted to conﬁrm the strength of these ﬁndings.
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